Literature DB >> 30105793

Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma.

Anabel Rodriguez1, Santiago Zugbi2, Flavio Requejo3, Alejandra Deu1, Claudia Sampor1, Mariana Sgroi4, Andrea Bosaleh5, Adriana Fandiño4, Paula Schaiquevich2,6, Guillermo Chantada1,6.   

Abstract

Patients with retinoblastoma and central nervous system (CNS) involvement are rarely curable with available treatments. We designed a high-dose intra-arterial regimen targeting the ophthalmic artery and chiasm combined with intrathecal chemotherapy to treat a 4-year-old patient with retinoblastoma metastasized to the CNS. After three cycles of this regimen, including carboplatin, melphalan, and intrathecal topotecan, a partial response of the orbital tumor mass and chiasmatic lesion, and complete response in the cerebrospinal fluid and bone marrow were achieved. This new treatment strategy may be explored as a treatment component for patients with overt extraocular retinoblastoma and CNS dissemination.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  intra-arterial chemotherapy; intrathecal topotecan; metastatic retinoblastoma

Mesh:

Substances:

Year:  2018        PMID: 30105793     DOI: 10.1002/pbc.27385

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Intra-arterial chemotherapy in retinoblastoma - A paradigm change.

Authors:  Fairooz P Manjandavida; Christina Stathopoulos; Jing Zhang; Santhosh G Honavar; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2019-06       Impact factor: 1.848

Review 2.  Treatment of Retinoblastoma: What Is the Latest and What Is the Future.

Authors:  Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

Review 3.  Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future.

Authors:  Ling Wang; Shixu Li; Jun Mei; Lin Ye
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.